Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

APT and Atreus announce strategic R&D agreement
November 2007
SHARING OPTIONS:

BOSTON—Advanced Proteome Therapeutics Inc. (APT), a subsidiary of Advanced Proteome Therapeutics Corp., and Atreus Pharmaceuticals Inc. recently announced they have entered into a strategic research and development agreement for novel protein in vivo imaging agents using advanced site-directed peptide modification techniques developed by APT.

The first product target is intended for imaging the earliest changes associated with rheum-atoid arthritis. Under the deal, Atreus will have the exclusive right to commercialize the jointly developed agents in return for revenue-sharing payments to APT. Atreus will provide technical, clinical and market expertise to the program, as well as intellectual property rights.

 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.